Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation.

Institut Claudius Regaud, Toulouse, France.

Survival: monthsCountry:France
Toxiciy Grade:5City/State/Province:Toulouse
Treatments:Chemotherapy, RadiationHospital:Institut Claudius Regaud
Drugs:Journal:Link
Date:Aug 2007

Description:

Patients: This phase I study involved 13 patients with newly diagnosed glioblastoma multiforme that had not received any treatment except for biopsy or surgery. There were 8 men and 5 women; the median age was 55 years, ranging from 28 to 74.

Treatment: Patients were given radiation treatment and the chemotherapy drug Tipifarnib. This drug is thought to make cancer cells more sensitive to radiation therapy.

Toxicity: One patient died suddenly during the study. Another patient developed acute pneumonitis, grade 4 neutropenia, grade 2 thrombocytopenia, and grade 3 phlebitits (vein inflammation) and died thirty days later. Other toxicities included arthralgia, constipation, dysgeusia (a distorted sense of taste), nausea, rash, and stomatitis.

Results: The median overall survival was 12 months, ranging from 5.2-21.

Support: This research study was supported by Johnson & Johnson Pharmaceutical Research and Development. The drug Tipifarnib was developed by and provided for the study by Johnson & Johnson.

Correspondence: Dr. Elizabeth Cohen-Jonathan Moyal



Back